NO20072664L - Rapamycinanaloger og anvendelser derav for behandling av neurologiske, proliferative og inflamatoriske forstyrrelser - Google Patents

Rapamycinanaloger og anvendelser derav for behandling av neurologiske, proliferative og inflamatoriske forstyrrelser

Info

Publication number
NO20072664L
NO20072664L NO20072664A NO20072664A NO20072664L NO 20072664 L NO20072664 L NO 20072664L NO 20072664 A NO20072664 A NO 20072664A NO 20072664 A NO20072664 A NO 20072664A NO 20072664 L NO20072664 L NO 20072664L
Authority
NO
Norway
Prior art keywords
proliferative
neurological
applications
treatment
inflammatory disorders
Prior art date
Application number
NO20072664A
Other languages
English (en)
Norwegian (no)
Inventor
Kevin Pong
Edmund Idris Graziani
Jerauld Skotnicki
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of NO20072664L publication Critical patent/NO20072664L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20072664A 2004-12-20 2007-05-25 Rapamycinanaloger og anvendelser derav for behandling av neurologiske, proliferative og inflamatoriske forstyrrelser NO20072664L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63766604P 2004-12-20 2004-12-20
PCT/US2005/045551 WO2006068932A2 (en) 2004-12-20 2005-12-15 Rapamycin analogues and the uses thereof in the treatment of neurological, proliferative, and inflammatory disorders

Publications (1)

Publication Number Publication Date
NO20072664L true NO20072664L (no) 2007-06-25

Family

ID=36087657

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20072664A NO20072664L (no) 2004-12-20 2007-05-25 Rapamycinanaloger og anvendelser derav for behandling av neurologiske, proliferative og inflamatoriske forstyrrelser

Country Status (27)

Country Link
US (5) US7276498B2 (es)
EP (1) EP1828202B1 (es)
JP (1) JP5094406B2 (es)
KR (1) KR20070090913A (es)
CN (1) CN101084227B (es)
AR (1) AR052269A1 (es)
AT (1) ATE549342T1 (es)
AU (1) AU2005319454B2 (es)
BR (1) BRPI0519495A2 (es)
CA (1) CA2590155A1 (es)
CR (1) CR9148A (es)
DK (1) DK1828202T3 (es)
ES (1) ES2380779T3 (es)
GT (1) GT200500368A (es)
HK (1) HK1108442A1 (es)
HN (1) HN2005035605A (es)
IL (1) IL183664A (es)
MX (1) MX2007007408A (es)
NI (1) NI200700157A (es)
NO (1) NO20072664L (es)
NZ (1) NZ574663A (es)
PE (1) PE20060765A1 (es)
RU (1) RU2394036C2 (es)
SG (1) SG158143A1 (es)
TW (1) TW200628152A (es)
UA (1) UA94034C2 (es)
WO (1) WO2006068932A2 (es)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR040693A1 (es) 2002-07-30 2005-04-13 Wyeth Corp Formulaciones parenterales
GT200500035A (es) * 2004-03-02 2005-10-24 Macrolidos y metodos para producir los mismos
US7507752B2 (en) * 2004-06-03 2009-03-24 Wyeth Biosynthetic gene cluster for the production of a complex polyketide
WO2006068905A2 (en) * 2004-12-20 2006-06-29 Wyeth Rapamycin derivatives and the uses thereof in the treatment of neurological disorders
WO2006068932A2 (en) * 2004-12-20 2006-06-29 Wyeth Rapamycin analogues and the uses thereof in the treatment of neurological, proliferative, and inflammatory disorders
WO2007067565A1 (en) * 2005-12-07 2007-06-14 Wyeth Process for the preparation of purified crystalline cci-779
CA2630645A1 (en) * 2005-12-07 2007-06-14 Wyeth Scalable process for the preparation of a rapamycin 42-ester from a rapamycin 42-ester boronate
CA2630786A1 (en) * 2005-12-07 2007-06-14 Wyeth Methods for preparing crystalline rapamycin and for measuring crystallinity of rapamycin compounds using differential scanning calorimetry
BRPI0708611A2 (pt) * 2006-03-07 2011-06-07 Wyeth Corp composto; uso do composto na preparação de um medicamento para tratamento de um transtorno neurológico em um mamìmefo; método de preparação do composto; e método de tratamento de um transtorno neurológico em um mamìfero
US20100081681A1 (en) * 2006-08-16 2010-04-01 Blagosklonny Mikhail V Methods and compositions for preventing or treating age-related diseases
TW200824713A (en) * 2006-10-18 2008-06-16 Wyeth Corp Processes for the synthesis of individual isomers of mono-PEG CCI-779
US8998846B2 (en) 2006-11-20 2015-04-07 Lutonix, Inc. Drug releasing coatings for balloon catheters
US20080276935A1 (en) 2006-11-20 2008-11-13 Lixiao Wang Treatment of asthma and chronic obstructive pulmonary disease with anti-proliferate and anti-inflammatory drugs
US8414526B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Medical device rapid drug releasing coatings comprising oils, fatty acids, and/or lipids
US8425459B2 (en) 2006-11-20 2013-04-23 Lutonix, Inc. Medical device rapid drug releasing coatings comprising a therapeutic agent and a contrast agent
US8414910B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US9737640B2 (en) 2006-11-20 2017-08-22 Lutonix, Inc. Drug releasing coatings for medical devices
US8414909B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US8414525B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US9700704B2 (en) 2006-11-20 2017-07-11 Lutonix, Inc. Drug releasing coatings for balloon catheters
US20100196355A1 (en) * 2007-01-29 2010-08-05 Wyeth Immunophilin Ligands and Methods for Modulating Immunophilin and Calcium Channel Activity
JP2008305262A (ja) * 2007-06-08 2008-12-18 Konica Minolta Business Technologies Inc サーバ及びシンクライアント環境でのプリンタ紹介方法
KR101666228B1 (ko) 2007-09-28 2016-10-13 인트렉손 코포레이션 생물치료학적 분자를 발현시키기 위한 치료학적 유전자-스위치 작제물 및 생물반응기, 및 이의 용도
US8653045B2 (en) 2008-02-05 2014-02-18 The Johns Hopkins University Induction of thyroid iodide-handling gene expression in human cancers
WO2009105510A1 (en) * 2008-02-19 2009-08-27 Wyeth Methods for using rapamycin analogues in the treatment of neurological disorders
WO2010024898A2 (en) 2008-08-29 2010-03-04 Lutonix, Inc. Methods and apparatuses for coating balloon catheters
DK2365802T3 (da) 2008-11-11 2017-11-13 Univ Texas Mikrokapsler af rapamycin og anvendelse til behandling af cancer
DE102008060549A1 (de) 2008-12-04 2010-06-10 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Wirkstoff-Peptid-Konstrukt zur extrazellulären Anreicherung
CN102612564B (zh) 2009-04-10 2015-08-26 齐海燕 新的抗衰老试剂及其鉴别方法
US9283211B1 (en) 2009-11-11 2016-03-15 Rapamycin Holdings, Llc Oral rapamycin preparation and use for stomatitis
US20170079962A1 (en) 2009-11-11 2017-03-23 Rapamycin Holdings, Llc Oral Rapamycin Preparation and Use for Stomatitus
KR20130010121A (ko) 2010-03-23 2013-01-25 인트렉손 코포레이션 치료적 단백질을 조건부로 발현하는 벡터，상기 벡터를 포함하는 숙주 세포 및 이의 용도
ES2372077B2 (es) * 2010-06-24 2012-05-18 Universidad De Sevilla Uso de la rapamicina para el tratamiento de los déficits cognitivos asociados al s�?ndrome de down.
EP2446886A1 (en) * 2010-10-29 2012-05-02 Fondazione Telethon Autophagy regulators and the uses thereof in the treatment of collagen VI defective Muscular Dystrophies
AU2012225749B2 (en) 2011-03-04 2015-01-22 Intrexon Corporation Vectors conditionally expressing protein
EP2589383A1 (en) 2011-11-06 2013-05-08 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Berlin FKBP subtype-specific rapamycin analogue for use in treatment of diseases
CA2926747A1 (en) 2012-10-12 2014-04-17 Arlan RICHARDSON Use of mtor inhibitors to treat vascular cognitive impairment
ITMI20122065A1 (it) * 2012-12-03 2014-06-04 Univ Padova Uso dei correttori del cftr nel trattamento delle patologie del muscolo striato
DK2968281T3 (da) 2013-03-13 2020-11-02 Univ Texas Mtor-hæmmere til forebyggelse af vækst af tarmpolyp
US9700544B2 (en) 2013-12-31 2017-07-11 Neal K Vail Oral rapamycin nanoparticle preparations
DK3089737T3 (da) 2013-12-31 2021-12-13 Rapamycin Holdings Llc Orale rapamycin-nanopartikelpræparater og anvendelse.
GB2538747B (en) * 2015-05-27 2022-04-13 Airbus Operations Ltd A measuring apparatus for measuring properties of a surface
UY37343A (es) 2016-07-25 2018-02-28 Intrexon Corp Control del fenotipo en plantas
AU2017359342B2 (en) 2016-11-09 2022-02-17 Intrexon Corporation Frataxin expression constructs
ES2871499T3 (es) 2017-05-15 2021-10-29 Bard Inc C R Dispositivo médico con recubrimiento de elución de fármaco y capa intermedia
WO2020076738A2 (en) * 2018-10-12 2020-04-16 Bellicum Pharmaceuticals, Inc Protein-binding compounds
CN113226389B (zh) 2018-11-14 2022-11-08 乐通公司 在经改性设备表面上具有药物洗脱涂层的医疗设备
EP3952937A1 (en) 2019-04-08 2022-02-16 Bard Peripheral Vascular, Inc. Medical device with drug-eluting coating on modified device surface
CN116322677A (zh) * 2020-07-21 2023-06-23 艾奥维安制药公司 Mtorc1调节剂及其用途
CN115887452A (zh) * 2022-01-27 2023-04-04 中以海德人工智能药物研发股份有限公司 雷帕霉素在治疗或预防乙型肝炎中的应用

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1445742A1 (de) * 1963-11-06 1968-12-19 Bayer Ag Verfahren zur Herstellung von 2-Stellung substituierten Benzoxazinonen
DE1545824A1 (de) 1965-06-21 1969-12-11 Bayer Ag Verfahren zur Herstellung von 2-Sulfonamido- bzw. 2-Sulfonhydrazido-Benzoxazinonen
GB1325047A (en) * 1969-08-11 1973-08-01 Ciba Geigy Ag Rifamycin compounds and processes for their manufacture
US3686238A (en) * 1970-01-19 1972-08-22 Syntex Corp Glycerol esterified with 2-naphthyl-acetic acids and fatty acids
US3900465A (en) * 1973-04-05 1975-08-19 Lepetit Spa 3-formylrifamycin azines
US3905981A (en) * 1973-10-12 1975-09-16 Research Corp N-dealkylation of tertiary amines
US4127720A (en) * 1977-09-21 1978-11-28 Bristol-Myers Company Pyrimido[2,1-a]isoquinoline derivatives having antiallergy activity
JPH0262875A (ja) 1988-05-23 1990-03-02 Wakunaga Pharmaceut Co Ltd 新規イソインドリン誘導体
WO1991019495A1 (en) 1990-06-11 1991-12-26 Fujisawa Pharmaceutical Co., Ltd. Use of a macrolide compound such as fk 506 for manufacturing a medicament for treating idiopathic thrombocytopenic purpura and basedow's disease
DE4021404A1 (de) 1990-07-05 1992-01-09 Sandoz Ag Heteroatome enthaltende trycyclische verbindungen, verfahren zu ihrer herstellung und ihre verwendung
US5023262A (en) * 1990-08-14 1991-06-11 American Home Products Corporation Hydrogenated rapamycin derivatives
GB2249027A (en) 1990-10-23 1992-04-29 Fujisawa Pharmaceutical Co Use of macrolide compounds for hepatic failure
WO1992013862A1 (en) 1991-02-05 1992-08-20 Fujisawa Pharmaceutical Co., Ltd. Lactone compounds
EP0642516B1 (en) 1991-09-05 2002-06-05 Abbott Laboratories Macrocyclic immunomodulators
US5604294A (en) * 1991-09-05 1997-02-18 Luly; Jay R. Macrocyclic immunomodulators
ZA935111B (en) 1992-07-17 1994-02-04 Smithkline Beecham Corp Rapamycin derivatives
ZA935112B (en) 1992-07-17 1994-02-08 Smithkline Beecham Corp Rapamycin derivatives
JPH08509499A (ja) 1993-04-23 1996-10-08 アボツト・ラボラトリーズ ラパマイシン結合体及び抗体
US7279561B1 (en) * 1993-04-23 2007-10-09 Wyeth Anti-rapamycin monoclonal antibodies
US5798355A (en) * 1995-06-07 1998-08-25 Gpi Nil Holdings, Inc. Inhibitors of rotamase enzyme activity
US5525610A (en) * 1994-03-31 1996-06-11 American Home Products Corporation 42-Epi-rapamycin and pharmaceutical compositions thereof
US5696135A (en) * 1995-06-07 1997-12-09 Gpi Nil Holdings, Inc. Inhibitors of rotamase enzyme activity effective at stimulating neuronal growth
TW427904B (en) * 1995-12-07 2001-04-01 American Home Prod Neuroprotective agents
US5717092A (en) * 1996-03-29 1998-02-10 Vertex Pharmaceuticals Inc. Compounds with improved multi-drug resistance activity
US5780484A (en) * 1996-11-13 1998-07-14 Vertex Pharmaceuticals Incorporated Methods for stimulating neurite growth with piperidine compounds
US6187784B1 (en) * 1998-06-03 2001-02-13 Gpi Nil Holdings, Inc. Pipecolic acid derivative hair growth compositions and uses
WO1999062483A1 (en) 1998-06-03 1999-12-09 Gpi Nil Holdings, Inc. Pipecolic acid derivative hair growth compositions and uses
US6376517B1 (en) 1998-08-14 2002-04-23 Gpi Nil Holdings, Inc. Pipecolic acid derivatives for vision and memory disorders
DK1105395T3 (da) 1998-08-17 2002-10-14 Wyeth Corp Fotoringsluttede rapamyciner
US6015809A (en) * 1998-08-17 2000-01-18 American Home Products Corporation Photocyclized rapamycin
WO2000034239A2 (en) 1998-12-08 2000-06-15 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
JP2003508535A (ja) 1999-09-09 2003-03-04 メルク エンド カムパニー インコーポレーテッド プレニル−タンパク質トランスフェラーゼのインヒビター
US6569867B2 (en) * 1999-10-01 2003-05-27 Kosan Biosciences, Inc. Polyketide derivatives
AU2748701A (en) 1999-10-29 2001-06-06 Kosan Biosciences, Inc. Rapamycin analogs
WO2001087884A2 (en) 2000-05-17 2001-11-22 Kosan Biosciences, Inc. Polyketide derivatives
MXPA04001524A (es) 2001-08-22 2004-05-31 Wyeth Corp 29-enoles de rapamicina.
EP1419153A1 (en) 2001-08-22 2004-05-19 Wyeth Rapamycin dialdehydes
EP1521828B1 (en) 2002-07-16 2015-07-01 Buck Institute for Research on Aging Production of polyketides
DE102004049700B4 (de) 2004-10-12 2007-10-18 Aircabin Gmbh Kraftunterstützungsvorrichtung mit lastabhängiger Kraftunterstützung
WO2006068932A2 (en) * 2004-12-20 2006-06-29 Wyeth Rapamycin analogues and the uses thereof in the treatment of neurological, proliferative, and inflammatory disorders
WO2006068905A2 (en) 2004-12-20 2006-06-29 Wyeth Rapamycin derivatives and the uses thereof in the treatment of neurological disorders
BRPI0708611A2 (pt) * 2006-03-07 2011-06-07 Wyeth Corp composto; uso do composto na preparação de um medicamento para tratamento de um transtorno neurológico em um mamìmefo; método de preparação do composto; e método de tratamento de um transtorno neurológico em um mamìfero

Also Published As

Publication number Publication date
NI200700157A (es) 2008-04-21
CN101084227A (zh) 2007-12-05
TW200628152A (en) 2006-08-16
AU2005319454A1 (en) 2006-06-29
AU2005319454B2 (en) 2012-08-09
US20090203682A1 (en) 2009-08-13
CN101084227B (zh) 2011-11-16
NZ574663A (en) 2010-05-28
HN2005035605A (es) 2010-08-05
JP5094406B2 (ja) 2012-12-12
US20080004264A1 (en) 2008-01-03
KR20070090913A (ko) 2007-09-06
US7276498B2 (en) 2007-10-02
EP1828202A2 (en) 2007-09-05
AR052269A1 (es) 2007-03-07
US7795252B2 (en) 2010-09-14
MX2007007408A (es) 2007-07-12
US20090239855A1 (en) 2009-09-24
US7560457B2 (en) 2009-07-14
US20070142423A1 (en) 2007-06-21
CR9148A (es) 2007-11-23
WO2006068932A3 (en) 2006-10-19
RU2394036C2 (ru) 2010-07-10
HK1108442A1 (en) 2008-05-09
US7470682B2 (en) 2008-12-30
WO2006068932A2 (en) 2006-06-29
RU2007119584A (ru) 2009-01-27
IL183664A (en) 2012-06-28
ES2380779T3 (es) 2012-05-18
DK1828202T3 (da) 2012-05-07
PE20060765A1 (es) 2006-10-02
JP2008524240A (ja) 2008-07-10
US20060135549A1 (en) 2006-06-22
IL183664A0 (en) 2007-09-20
BRPI0519495A2 (pt) 2009-02-03
ATE549342T1 (de) 2012-03-15
SG158143A1 (en) 2010-01-29
UA94034C2 (ru) 2011-04-11
GT200500368A (es) 2006-07-13
EP1828202B1 (en) 2012-03-14
CA2590155A1 (en) 2006-06-29

Similar Documents

Publication Publication Date Title
NO20072664L (no) Rapamycinanaloger og anvendelser derav for behandling av neurologiske, proliferative og inflamatoriske forstyrrelser
NO20072665L (no) Rapamycinderivater og deres anvendelse i behandling av nevrologiske lidelser
EA200900663A1 (ru) Лечение синдрома "сухого глаза"
EA200300717A1 (ru) Гетероциклилиндазольные и -азаиндазольные соединения в качестве 5-гидрокситриптамин-6-лигандов
BRPI0508051A (pt) derivados de heteroarilaminopirazol utilizáveis para o tratamento de diabetes
NO20070247L (no) Amino-5,5-difenylimidazolonderivater for inhibisjon av beta-sekretase
DK1955700T3 (da) Terapeutisk behandling af androgenreceptor-betingede lidelser
CY2013022I1 (el) Συνθεσεις για την θεραπευτικη αγωγη γαστρεντερικων διαταραχων
EA200870093A1 (ru) Применение производных бензоконденсированного гетероциклического сульфамида для лечения ожирения
AR028824A1 (es) Compuestos antagonistas npy-5 y su uso en la manufactura de medicamentos.
ATE361288T1 (de) N-(3,-dimethylindolin-6-yl)ä2-ä(4-
ATE427759T1 (de) Behandlung von fettsucht und verbundenen erkrankungen
ECSP066986A (es) Beta-carbolinas utiles para tratar enfermedades inflamatorias
CY1106424T1 (el) Παραγωγα ν-φαινυλ-πυρρολ γουανιδινης ως συνδετες υποδοχεις μελανοκορτινης
ATE384058T1 (de) Thiazolderivate
DE602004012858D1 (de) 2-aminobenzothiazole als cb1 rezeptor inverse agonisten
BR0316723A (pt) Derivados de anilinopirazol úteis para o tratamento de diabetes
MXPA04005847A (es) Compuestos derivados de 4-sulfuro/sulfoxido/sulfonil-1h-pirazolilo, para uso en enfermedades asociadas con el receptor 5-ht2c.
BR0215151A (pt) Derivados de azaindolilalquilamina como ligandos de 5-hidroxitriptamina-6
EA200301142A1 (ru) Производные гетероциклилокси-, -тиокси- и -аминобензазола в качестве лигандов 5-гидрокситриптамина-6
WO2004074243A3 (en) Heterocyclyl-3-sulfonylindazoles as 5-hydroxytryptamine-6 ligands
EA200300716A1 (ru) Гетероциклилалкилиндольные или -азаиндольные соединения в качестве лиганд 5-гидрокситриптамина-6
ECSP045156A (es) Derivados de indolilalquilamina como ligandos 5-hidroxitriptamina-6
DE60014136D1 (de) Sapogenin derivate zur behandlung von kognitiven störungen
EA200600071A1 (ru) Производные n-фенилпиперазина и способы профилактики или лечения заболеваний, связанных с 5ht-рецептором

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application